Skip to content

Study · Systematic review · n = 7,245 · 2022

7 results

Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis.

Guan R, Yang Q, Yang X, Du W, Li X, Ma G

Frontiers in pharmacology14 Oct 2022Cited by 20 (Europe PMC)

PMID36313305 (opens in a new tab)PMCIDPMC9613929 (opens in a new tab)DOI10.3389/fphar.2022.998816 (opens in a new tab)PepBankPUB-36313305
Download PDFPubMedAsk about this study
Jump to 7 results

Summary

Background: In light of clinical trials comparing different doses of tirzepatide with selective glucagon-like peptide-1 receptor agonist (GLP1-RA) or insulin analogue, a bayesian network meta-analysis was conducted to investigate the efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus (T2DM). Methods: We systematically searched PubMed, Embase, Web of science, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov from their inception to 2 May 2022. Final included studies met the eligibility criteria and methodological quality recommendations. Data analysis was performed using Stata 15.1 software. Each outcome was presented as a mean difference or an odds ratio, and the surface under the cumulative ranking curve value (SCURA). Results: Ultimately, eight eligible RCTs involving 7245 patients were included. Generally speaking, compared with basal insulin (glargine or degludec); selective GLP1-RA (dulaglutide or semaglutide once weekly), 10 and 15 mg of tirzepatide exhibited better antidiabetic and weight-loss effect, especially, 15 mg of tirzepatide was dominant on reducing glycated hemoglobin (SCURA probability: 93.5%), body weight (99.7%), and fasting serum glucose (86.6%). As for safety, insulin caused less gastrointestinal events (93.5%), and there was no statistical difference between GLP1-RA and tirzepatide. Conclusion: Compare with insulin and GLP1-RA, tirzepatide display favorable efficacy and acceptable safety for T2DM patients. More well-designed RCTs are needed to evaluate its clinical performance with higher doses of GLP1-RA and determine its potential cardiovascular benefits.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a network meta-analysis in adults with type 2 diabetes, tirzepatide 10 and 15 mg had a better antidiabetic effect than basal insulin or selective GLP-1 receptor agonists.

    In plain wordsIn a pooled analysis of trials in adults with type 2 diabetes, tirzepatide controlled blood sugar better than basal insulin or GLP-1 drugs.

    Peptide
    Tirzepatide
    Outcome
    IncreaseAntidiabetic effect of tirzepatide 10 and 15 mg
    Study

    n = 7,245

    Comparator
    Basal insulin and selective GLP-1 receptor agonists
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 mg and 15 mgAs given in this study (human).

    Source sentences

    Summary
    compared with basal insulin (glargine or degludec); selective GLP1-RA (dulaglutide or semaglutide once weekly), 10 and 15 mg of tirzepatide exhibited better antidiabetic and weight-loss effect
    1 context sentence
    Summary · context
    Ultimately, eight eligible RCTs involving 7245 patients were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In a network meta-analysis in adults with type 2 diabetes, tirzepatide 10 and 15 mg had a better weight-loss effect than basal insulin or selective GLP-1 receptor agonists.

    In plain wordsIn a pooled analysis of trials in adults with type 2 diabetes, tirzepatide led to more weight loss than basal insulin or GLP-1 drugs.

    Peptide
    Tirzepatide
    Outcome
    IncreaseWeight-loss effect of tirzepatide 10 and 15 mg
    Study

    n = 7,245

    Comparator
    Basal insulin and selective GLP-1 receptor agonists
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 mg and 15 mgAs given in this study (human).

    Source sentences

    Summary
    compared with basal insulin (glargine or degludec); selective GLP1-RA (dulaglutide or semaglutide once weekly), 10 and 15 mg of tirzepatide exhibited better antidiabetic and weight-loss effect
    1 context sentence
    Summary · context
    Ultimately, eight eligible RCTs involving 7245 patients were included.
  3. 03HumanSystematic reviewEfficacy outcome

    In a network meta-analysis in adults with type 2 diabetes, tirzepatide 15 mg ranked first for reducing glycated hemoglobin (SCURA probability 93.5%).

    In plain wordsIn a pooled analysis of trials in adults with type 2 diabetes, tirzepatide 15 mg ranked best for lowering long-term blood sugar.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c reduction ranking, tirzepatide 15 mg
    Study

    n = 7,245

    Comparator
    Basal insulin and selective GLP-1 receptor agonists
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mgAs given in this study (human).

    Measurements

    SCURA probability, HbA1c
    93.5%
    tirzepatide 15 mg

    Source sentences

    Summary
    15 mg of tirzepatide was dominant on reducing glycated hemoglobin (SCURA probability: 93.5%)
    1 context sentence
    Summary · context
    Ultimately, eight eligible RCTs involving 7245 patients were included.
  4. 04HumanSystematic reviewEfficacy outcome

    In a network meta-analysis in adults with type 2 diabetes, tirzepatide 15 mg ranked first for reducing body weight (SCURA probability 99.7%).

    In plain wordsIn a pooled analysis of trials in adults with type 2 diabetes, tirzepatide 15 mg ranked best for lowering body weight.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight reduction ranking, tirzepatide 15 mg
    Study

    n = 7,245

    Comparator
    Basal insulin and selective GLP-1 receptor agonists
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    15 mgAs given in this study (human).

    Measurements

    SCURA probability, body weight
    99.7%
    tirzepatide 15 mg

    Source sentences

    Summary
    15 mg of tirzepatide was dominant on reducing glycated hemoglobin (SCURA probability: 93.5%), body weight (99.7%)
    1 context sentence
    Summary · context
    Ultimately, eight eligible RCTs involving 7245 patients were included.
  5. 05HumanSystematic reviewEfficacy outcome

    In a network meta-analysis in adults with type 2 diabetes, tirzepatide 15 mg ranked first for reducing fasting serum glucose (SCURA probability 86.6%).

    In plain wordsIn a pooled analysis of trials in adults with type 2 diabetes, tirzepatide 15 mg ranked best for lowering fasting blood sugar.

    Peptide
    Tirzepatide
    Outcome
    DecreaseFasting serum glucose reduction ranking, tirzepatide 15 mg
    Study

    n = 7,245

    Comparator
    Basal insulin and selective GLP-1 receptor agonists
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mgAs given in this study (human).

    Measurements

    SCURA probability, fasting serum glucose
    86.6%
    tirzepatide 15 mg

    Source sentences

    Summary
    15 mg of tirzepatide was dominant on reducing glycated hemoglobin (SCURA probability: 93.5%), body weight (99.7%), and fasting serum glucose (86.6%)
    1 context sentence
    Summary · context
    Ultimately, eight eligible RCTs involving 7245 patients were included.
  6. 06HumanSystematic reviewSafety outcome

    In a network meta-analysis in adults with type 2 diabetes, insulin caused fewer gastrointestinal events than tirzepatide.

    In plain wordsIn a pooled analysis of trials in adults with type 2 diabetes, insulin caused fewer stomach and gut side effects than tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseGastrointestinal events versus insulin
    Study

    n = 7,245

    Comparator
    Basal insulin
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    insulin caused less gastrointestinal events (93.5%)
    1 context sentence
    Summary · context
    Ultimately, eight eligible RCTs involving 7245 patients were included.
  7. 07HumanSystematic reviewSafety outcome

    In a network meta-analysis in adults with type 2 diabetes, there was no statistical difference in gastrointestinal events between GLP-1 receptor agonists and tirzepatide.

    In plain wordsIn a pooled analysis of trials in adults with type 2 diabetes, tirzepatide and GLP-1 drugs did not differ in stomach and gut side effects.

    Peptide
    Tirzepatide
    Outcome
    No significant changeGastrointestinal events versus GLP-1 receptor agonists
    Study

    n = 7,245

    Comparator
    Selective GLP-1 receptor agonists
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    there was no statistical difference between GLP1-RA and tirzepatide.
    1 context sentence
    Summary · context
    Ultimately, eight eligible RCTs involving 7245 patients were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.